Objectives: To evaluate the short-(first year) and long-term (second year) cost of cardiovascular events (CVEs) in Belgium. MethOds: The analysis included myocardial infarction (MI, excluding revascularization), unstable angina (UA, excluding revascularization), heart failure (HF), ischemic/hemorrhagic stroke (IS/HS) and transient ischemic attack (TIA). Coronary revascularization procedures (weighted average of coronary artery bypass grafting [CABG] and percutaneous coronary intervention [PCI]) were also evaluated. Index hospitalization costs (year 2012) as well as re-hospitalization costs up to 2 year after the index hospitalization were derived from the Belgian IMS real-world Hospital Disease Database (HDD). Other follow-up costs (rehabilitation, outpatient visits and ambulatory resource use [tests, imaging and drugs]) over 2 years were assessed by an independent 2-round expert-panel in 2014 (5 cardiologists, 6 neurologists). Costs of fatal CVEs were evaluated through the HDD. The combined perspective of public health care payer and patient was applied. Costs (€ in 2014) were calculated as unit costs (official listings) multiplied by the number of resources used. Results: Total costs in the first year after CVEs ranged between

No abstract

No abstract

No abstract

methods has intrinsic limitations linked to the many assumptions that need to be made. Nonetheless, it provides to be a valuable tool in assessing portfolio assets. Our experience in access made us aware of the healthtechnology-valuation hurdles that may affect the cash flows generated by a patented asset over its lifetime. Thus, we suggest to shift the access mindset to earlier decision points in the drug development process. In this fashion, more valuable assets are likely to be brought to the clinic over the next decade.